Subject(s)
Erectile Dysfunction , 3',5'-Cyclic-GMP Phosphodiesterases/metabolism , Cardiovascular Diseases/etiology , Cardiovascular Diseases/metabolism , Cyclic Nucleotide Phosphodiesterases, Type 5 , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Erectile Dysfunction/drug therapy , Erectile Dysfunction/enzymology , Erectile Dysfunction/etiology , Erectile Dysfunction/metabolism , Humans , Male , Nitric Oxide/metabolismABSTRACT
An open trial performed in 2001 by the Research Institute of Urology has demonstrated good efficacy and safety of rectal suppositoria Vitaprost, the active substance of which is a complex of water-soluble biologically active peptides isolated from bovine prostate, in combined treatment of chronic bacterial and abacterial prostatitis in patients of all ages including those with concomitant adenoma. Current comparative clinical trial has shown that Vitaprost tablets in combination with nonsteroid anti-inflammatory drugs effectively treat prostatic inflammation in patients with chronic abacterial prostatitis, produce more potent and stable effect than monotherapy with ketonal. The absence of side effects and negative alterations in clinical and biochemical blood and urine parameters evidences for good tolerance and safety of Vitaprost tablets. Vitaprost tablets can be used in therapy of chronic abacterial prostatitis for raising efficacy of the standard treatment in patients of different ages and having associated diseases.
